Hyperion Therapeutics (FRA:0HY) Inventory-to-Revenue : 0.16 (As of Mar. 2015)

View and export this data going back to . Start your Free Trial

What is Hyperion Therapeutics Inventory-to-Revenue?

Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue. Hyperion Therapeutics's Average Total Inventories for the quarter that ended in Mar. 2015 was €4.5 Mil. Hyperion Therapeutics's Revenue for the three months ended in Mar. 2015 was €28.8 Mil. Hyperion Therapeutics's Inventory-to-Revenue for the quarter that ended in Mar. 2015 was 0.16.

Hyperion Therapeutics's Inventory-to-Revenue for the quarter that ended in Mar. 2015 increased from Dec. 2014 (0.14) to Dec. 2014 (0.16)

An increase in Inventory-to-Revenue from one quarter to the next indicates that one of the following is happening:

1. investment in inventory is growing more rapidly than revenue
2. revenue are dropping
No matter which situation is causing the problem, an increase in the Inventory-to-Revenue may signal an oncoming cash flow problem.

Days Inventory indicates the number of days of goods in sales that a company has in the inventory. Hyperion Therapeutics's Days Inventory for the three months ended in Mar. 2015 was 114.93.

Inventory Turnover measures how fast the company turns over its inventory within a year. Hyperion Therapeutics's Inventory Turnover for the quarter that ended in Mar. 2015 was 0.79.

Hyperion Therapeutics Inventory-to-Revenue Historical Data

The historical data trend for Hyperion Therapeutics's Inventory-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Hyperion Therapeutics Inventory-to-Revenue Chart

Hyperion Therapeutics Annual Data

Trend

Dec10

Dec11

Dec12

Dec13

Dec14

Inventory-to-Revenue

0.08

0.03

Hyperion Therapeutics Quarterly Data
	Dec10	Mar11	Jun11	Sep11	Dec11	Mar12	Jun12	Sep12	Dec12	Mar13	Jun13	Sep13	Dec13	Mar14	Jun14	Sep14	Dec14	Mar15
Inventory-to-Revenue	Get a 7-Day Free Trial													0.16	0.08	0.13	0.14	0.16

Competitive Comparison of Hyperion Therapeutics's Inventory-to-Revenue

For the Biotechnology subindustry, Hyperion Therapeutics's Inventory-to-Revenue, along with its competitors' market caps and Inventory-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Hyperion Therapeutics's Inventory-to-Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Hyperion Therapeutics's Inventory-to-Revenue distribution charts can be found below:

* The bar in red indicates where Hyperion Therapeutics's Inventory-to-Revenue falls into.

Hyperion Therapeutics Inventory-to-Revenue Calculation

Hyperion Therapeutics's Inventory-to-Revenue for the fiscal year that ended in Dec. 2014 is calculated as

	Inventory-to-Revenue (A: Dec. 2014 )
=	Average Total Inventories					/	Revenue
=	( (Total Inventories (A: Dec. 2013 )	+	Total Inventories (A: Dec. 2014 ))	/	count )	/	Revenue (A: Dec. 2014 )
=	( (2.564	+	3.748)	/	2 )	/	92.117
=	3.156					/	92.117
=	0.03

Hyperion Therapeutics's Inventory-to-Revenue for the quarter that ended in Mar. 2015 is calculated as

	Inventory-to-Revenue (Q: Mar. 2015 )
=	Average Total Inventories					/	Revenue
=	( (Total Inventories (Q: Dec. 2014 )	+	Total Inventories (Q: Mar. 2015 ))	/	count )	/	Revenue (Q: Mar. 2015 )
=	( (3.748	+	5.172)	/	2 )	/	28.822
=	4.46					/	28.822
=	0.15

Hyperion Therapeutics (FRA:0HY) Inventory-to-Revenue Explanation

An increase in Inventory-to-Revenue from one quarter to the next indicates that one of the following is happening:

Likewise, a decrease in the Inventory-to-Revenue from one quarter to next indicates that one of these is occurring:

1. investment in inventory is shrinking in relation to revenue
2. revenue are increasing
No matter which situation is causing the reduction in the Inventory-to-Revenue, either one suggests that business's inventory levels and its cash flow are effectively managed.

More Related Terms:

1. Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

Hyperion Therapeutics's Days Inventory for the three months ended in Mar. 2015 is calculated as:

Days Inventory	=	Average Total Inventories (Q: Mar. 2015 )	/	Cost of Goods Sold (Q: Mar. 2015 )	*	Days in Period
	=	4.46	/	3.541	*	365 / 4
	=	114.93

2. Inventory Turnover measures how fast the company turns over its inventory within a year.

Hyperion Therapeutics's Inventory Turnover for the quarter that ended in Mar. 2015 is calculated as

Inventory Turnover	=	Cost of Goods Sold (Q: Mar. 2015 )	/	Average Total Inventories (Q: Mar. 2015 )
	=	3.541	/	4.46
	=	0.79

Hyperion Therapeutics Inventory-to-Revenue Related Terms

Thank you for viewing the detailed overview of Hyperion Therapeutics's Inventory-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Hyperion Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Hyperion Therapeutics Inc (FRA:0HY) » Definitions » Inventory-to-Revenue

Comparable Companies

Traded in Other Exchanges

N/A

Address

Website

http://www.hyperiontx.com

Hyperion Therapeutics Inc., was incorporated in Delaware on November 1, 2006. The Company completed its initial public offering on July 2012. It is a commercial biopharmaceutical company, engaged in the development and commercialization of novel therapeutics to treat disorders in the areas of orphan diseases and hepatology. Its products, RAVICTI (glycerol phenylbutyrate) Oral liquid, BUPHENYL and AMMONAPS (sodium phenylbutyrate) Tablets and Powder, are designed to lower ammonia in the blood. The Company has developed RAVICTI to treat urea cycle disorders including 7 of the 8 prevalent UCD subtypes, and is developing glycerol phenylbutyrate, the active pharmaceutical ingredient in RAVICTI, to treat hepatic encephalopathy. RAVICTI is indicated for use as a nitrogen-binding agent for chronic management of adult and pediatric patients above 2 years of age with urea cycle disorders who cannot be managed by dietary protein restriction and/or amino acid supplementation alone. It distributes RAVICTI through two specialty pharmacies with a single dedicated call center responsible for interfacing with patients, physicians and payors. BUPHENYL is indicated in all patients with neonatal-onset deficiency (complete enzymatic deficiency, presenting within the first 28 days of life). It is also indicated in patients with late-onset disease (partial enzymatic deficiency, presenting after the first month of life) who have a history of hyperammonemic encephalopathy. The Company faces competition from established pharmaceutical and biotechnology companies, as well as from academic institutions, government agencies and private and public research institutions, among others, which may in the future develop products to treat UCD or HE. The Company is subject to numerous federal, state and local laws relating to such matters as safe working conditions, manufacturing practices, environmental protection, fire hazard control, and disposal of hazardous or potentially hazardous substances.

Hyperion Therapeutics Headlines

No Headlines